Evidence map›Paper›PMID 34198618›Full record

ReviewNutrients2021

Chrysin: Perspectives on Contemporary Status and Future Possibilities as Pro-Health Agent.

Monika Stompor-Gorący, Agata Bajek-Bil, Maciej Machaczka

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
7.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 142 citations in OpenAlex.

  1. Tailoring the biological activity of oxorhenium(V) complexes through Chrysin ligand functionalization.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026
    Article
  2. Review
  3. Chemical Characterisation ofPlants (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Therapeutic Perspectives of Aminoflavonoids-A Review.International journal of molecular sciences · 2025
    Review
  20. Anticancer Activity of Ether Derivatives of Chrysin.Molecules (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Monika Stompor-GorącyDepartment of Human Pathophysiology, Institute of Medical Sciences, University of Rzeszów, Warzywna 1a, 35-310 Rzeszów, Poland.ORCID 0000-0001-5618-8899
Agata Bajek-BilFaculty of Chemistry, Rzeszow University of Technology, 35-959 Rzeszów, Poland.
Maciej MachaczkaDepartment of Human Pathophysiology, Institute of Medical Sciences, University of Rzeszów, Warzywna 1a, 35-310 Rzeszów, Poland.
Karolinska Institutet · SERzeszów University of Technology · PLUniversity of Rzeszów · PL

Funding

Ministerstwo Nauki i Szkolnictwa Wyższego STYP/15/0763/E-546/2020
6 · The paper itself

Abstract

Chrysin belongs to the group of natural polyphenols. It can be found, among others, in honey, propolis and fruits and has a wide range of biological activities, including the prevention of oxidative stress, inflammation, neurodegeneration and carcinogenesis. Being a part of the human diet, chrysin is considered to be a promising compound to be used in the prevention of many diseases, including cancers, diabetes and neurodegenerative diseases such as Alzheimer's or Parkinson's. Nevertheless, due to the low solubility of chrysin in water and under physiological conditions, its bioavailability is low. For this reason, attempts at its functionalization have been undertaken, aiming to increase its absorption and thus augment its in vivo therapeutic efficacy. The aim of this review is to summarize the most recent research on chrysin, including its sources, metabolism, pro-health effects and the effects of its functionalization on biological activity and pharmacological efficacy, evaluated both in vitro and in vivo.

Indexed as

FlavonoidsAnimalsAntineoplastic AgentsBiological AvailabilityDrug CarriersEye DiseasesHumansInflammationLiverNeoplasmsNeurodegenerative DiseasesNeuroprotectionPolyphenolsSkin DiseasesAntineoplastic AgentschrysinDrug CarriersFlavonoidsPolyphenolsanticancer activityantioxidantschrysinimmunomodulatorsneuroprotection

Identifiers

PMID34198618
PMCPMC8232110
OpenAlexW3169126012

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.